Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764198 in focal segmental glomerulosclerosis
2020-000384-23Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apecotrep in focal segmental glomerulosclerosis (FSGS) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Proportion of patients with at least 25% reduction in 24-hour urine protein creatinine ratio at week 12. Started Mar 2022; status: active.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2020-000384-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000384-23.